Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
American Journal of Clinical Oncology|February 1, 1988
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinomaS Wadler, A I Einzig, J P Dutcher, et al.Investigational New Drugs|September 18, 1998
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancyA I Einzig, P H Wiernik, S Wadler, et al.Cancer Investigation|January 1, 1985
Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium)A I Einzig, R J Gralla, B R Leyland-Jones, et al.Medical Oncology (Northwood, London, England)|June 1, 1996
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293A I Einzig, D Neuberg, S C Remick, et al.Investigational New Drugs|February 1, 1991
A phase II study of taxol in patients with malignant melanomaA I Einzig, H Hochster, P H Wiernik, et al.Investigational New Drugs|January 1, 1997
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumorsN T Sklarin, C D Lathia, L Benson, et al.Cancer Treatment Reports|January 1, 1987
High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responsesS E Krown, D Mintzer, S Cunningham-Rundles, et al.Neurology|March 1, 1989
Taxol produces a predominantly sensory neuropathyR B Lipton, S C Apfel, J P Dutcher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1985
Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysisJ M Mondesir, J M Bidart, A Goodman, et al.Pageof 2